Vera Therapeutics [VERA] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Vera Therapeutics Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Vera Therapeutics Inc. wins in 6 metrics, Axsome Therapeutics Inc. wins in 8 metrics, with 0 ties. Axsome Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vera Therapeutics Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) N/A -50.54 N/A
Price-to-Book Ratio 4.75 105.31 Vera Therapeutics Inc.
Debt-to-Equity Ratio 12.79 247.03 Vera Therapeutics Inc.
PEG Ratio -13.23 0.79 Axsome Therapeutics Inc.
EV/EBITDA -7.10 -57.70 Vera Therapeutics Inc.
Profit Margin (TTM) 0.00% -28.69% Vera Therapeutics Inc.
Operating Margin (TTM) 0.00% -18.38% Vera Therapeutics Inc.
Return on Equity -50.71% -252.12% Vera Therapeutics Inc.
Return on Assets (TTM) -28.36% -16.81% Axsome Therapeutics Inc.
Free Cash Flow (TTM) $-241.73M $-93.89M Axsome Therapeutics Inc.
1-Year Return 87.44% 122.97% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 14.64 N/A
Enterprise Value $2.24B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio N/A 14.47 N/A
Gross Profit Margin (TTM) N/A 93.71% N/A
Revenue per Share (TTM) N/A $13 N/A
Earnings per Share (Diluted) $-4.66 $-3.69 Axsome Therapeutics Inc.
Beta (Stock Volatility) 1.17 0.47 Axsome Therapeutics Inc.
Short % of Float 15.51% 6.56% Axsome Therapeutics Inc.

Vera Therapeutics Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

VERA
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vera Therapeutics Inc.0.03%-8.75%-11.94%-20.43%-24.21%-35.68%
Axsome Therapeutics Inc.5.09%-0.45%4.37%42.32%57.95%30.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vera Therapeutics Inc.87.44%281.53%141.47%208.87%208.87%208.87%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Vera Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricVERAAXSM
Market Information
Market Cap i$2.75B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,253,284592,425
90 Day Avg. Volume i1,262,295602,162
Last Close$31.27$233.47
52 Week Range$19.07 - $56.05$96.09 - $238.56
% from 52W High-44.21%-2.13%
All-Time High$56.04 (Dec 24, 2025)$238.56 (May 26, 2026)
% from All-Time High-44.20%-2.13%
Growth Metrics
Quarterly Revenue GrowthN/A0.65%
Quarterly Earnings GrowthN/A0.65%
Financial Health
Profit Margin (TTM) i0.00%-0.29%
Operating Margin (TTM) i0.00%-0.18%
Return on Equity (TTM) i-0.51%-2.52%
Debt to Equity (MRQ) i12.79247.03
Cash & Liquidity
Book Value per Share (MRQ)$8.48$1.74
Cash per Share (MRQ)$10.01$6.31
Operating Cash Flow (TTM) i$-241,104,000$-93,405,000
Levered Free Cash Flow (TTM) i$-139,023,504$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vera Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricVERA (Apr 24, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-50.54
Forward P/E i-13.2329.85
PEG Ratio i-13.230.79
Price to Sales (TTM) iN/A14.64
Price to Book (MRQ) i4.75105.31
Market Capitalization
Market Capitalization i$2.75B$9.51B
Enterprise Value i$2.24B$9.24B
Enterprise Value Metrics
Enterprise to Revenue iN/A14.47
Enterprise to EBITDA i-7.10-57.70
Risk & Other Metrics
Beta i1.170.47
Book Value per Share (MRQ) i$8.48$1.74

Financial Statements Comparison: Vera Therapeutics Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVERA (2025)AXSM (2025)
Revenue/Sales i0638.50M
Cost of Goods Sold iN/A47.48M
COGS % of Revenue i-7.4%
Gross Profit iN/A591.02M
Gross Margin i-92.6%
Research & Development i215.26M183.28M
Operating Income (EBIT) i-315.47M-169.24M
Operating Margin i--26.5%
EBITDA i-291.62M-160.17M
EBITDA Margin i--25.1%
Pre-Tax Income i-299.61M-183.70M
Pre-Tax Income % of Revenue i--28.8%
Income Tax i1,000-530,000
Income Tax % of Revenue i--0.1%
Net Income (Profit) i-299.62M-183.17M
Profit Margin i--28.7%

Balance Sheet & Liquidity Metrics

MetricVERA (2025)AXSM (2025)
Cash & Equivalents i354.73M322.93M
Total Current Assets i728.88M588.99M
Total Current Assets % of Revenue i-92.2%
Total Current Liabilities i53.46M378.84M
Total Current Liabilities % of Revenue i-59.3%
Long-Term Debt i76.76M145.13M
Long-Term Debt % of Revenue i-22.7%
Total Shareholders Equity i604.52M88.30M
Retained Earnings i-760.87M-1.31B
Retained Earnings % of Revenue i--204.5%
Property, Plant & Equipment i1.37M562,000

Cash Flow Statement Comparison

MetricVERA (2025)AXSM (2025)
Operating Cash Flow i-244.64M-185.86M
Operating Cash Flow % of Revenue i--29.1%
Capital Expenditures i-630,000-480,000
Free Cash Flow i-241.73M-93.89M
FCF Margin i--14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricVERAAXSM
Shares Short i9.76M2.83M
Short Ratio i7.554.92
Short % of Float i15.51%6.56%
Shares Outstanding i71.27M50.88M
Float Shares i51.53M43.24M
% Held by Insiders i0.90%15.47%
% Held by Institutions i115.23%76.52%
% Held by Public i-16.13%8.01%

Dividend Analysis & Yield Comparison: Vera Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricVERAAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A